Robust and accurate biomarker tests to aid clinical decisions
Elecsys® β-Amyloid (1-42) CSF II and Elecsys® Phospho-Tau (181P) CSF are in vitro electrochemiluminescence immunoassays for the measurement of the β-Amyloid (1-42) (Abeta42) and Phospho-Tau (181P) (pTau181) protein concentrations in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a pTau181/Abeta42 ratio value.1
The Elecsys® Phospho-Tau (181P) CSF assay is not intended to be used as a stand-alone test and should only be used with the Elecsys® β-Amyloid (1-42) CSF II assay to calculate the ratio of phosphorylated Tau (181P) (pTau181) to β-Amyloid (1-42) (Abeta42) in CSF (pTau181/Abeta42 ratio).1
The use of the Elecsys® assays in the pTau181/Abeta42 ratio can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.2,3
A positive pTau181/Abeta42 ratio result in CSF does not establish a diagnosis of Alzheimer's disease (AD) and should always be interpreted in conjunction with clinical information.1